01
Company
Company
Vision and Values
Citizenship
Leadership Team
Board of Directors
Our Locations
Supply Chain Management
02
Products & Services
Products
R&D
Generics
Export Oncology
Facilities
Contract Research
03
Investors
Investors
Corporate Governance
Monthly Sales
Quarterly Results
Shareholders Services
Financial Calendar
04
Newsroom
Contact Us
Language
Languages
English
Chinese
Alvogen Korea
Company
Products & Services
Investors
Newsroom
Company
Vision and Values
Citizenship
Leadership Team
Board of Directors
Our Locations
Supply Chain Management
Products
R&D
Generics
Export Oncology
Facilities
Contract Research
Investors
Corporate Governance
Monthly Sales
Quarterly Results
Shareholders Services
Financial Calendar
Skip Navigation
Investors
A Fast Growing Contender in Global Generics
Meet Management
Newsroom
In Focus
All articles
Investors
10 December 2024
Lotus Reported Unaudited November Revenues of NT$1,061 million, YTD Revenue Surpassing the Total Revenue for 2023
Investors
09 May 2024
Lotus announced 1Q24 financial results, full-year outlook unchanged
Business
06 May 2024
Lotus pharmaceuticals 1Q24 earnings call
Stock Information
Lotus is listed on Taiwan Stock Exchange
Code: 1795
Stock Quote
Market Observation Post System
TWSE, Taipei 101
Links
Document Center
Financial Information
Monthly sales
Quarterly Reports and Presentations
Shareholders Services
Shareholders meetings
Contacts
